Pharmaceutical

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.

Dec 22, 2023 - 18:00
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.
Read the original article

Tags:

Previous Article

Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval

Next Article

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

(Nanatinostat + valganciclovir) by Viracta Therapeutics...

Dec 24, 2023

J&J signs Stelara biosimilar settlement deal with Formycon and Fresenius

J&J signs Stelara biosimilar settlement deal with Formy...

Aug 8, 2023

STAT+: Prominent pharmaceutical industry ally Anna Eshoo to retire

STAT+: Prominent pharmaceutical industry ally Anna Esho...

Nov 21, 2023